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Background: Atrial arrhythmia (AA) is the most common complication after coronary artery bypass grafting (CABG).
Only beta-blockers and amiodarone have been convincingly shown to decrease its incidence. The effectiveness of
magnesium on this complication is still controversial. This meta-analysis was performed to evaluate the effect of
magnesium as a sole or adjuvant agent in addition to beta-blocker on suppressing postoperative AA after CABG.
Methods: We searched the PubMed, Medline, ISI Web of Knowledge, Cochrane library databases and online clinical
trial database up to May 2012. We used random effects model when there was significant heterogeneity between
trials and fixed effects model when heterogeneity was negligible.
Results: Five randomized controlled trials were identified, enrolling a total of 1251 patients. The combination of
magnesium and beta-blocker did not significantly decrease the incidence of postoperative AA after CABG versus
beta-blocker alone (odds ratio (OR) 1.12, 95% confidence interval (CI) 0.86-1.47, P = 0.40). Magnesium in addition to
beta-blocker did not significantly affect LOS (weighted mean difference −0.14 days of stay, 95% CI −0.58 to 0.29,
P = 0.24) or the overall mortality (OR 0.59, 95% CI 0.08-4.56, P = 0.62). However the risk of postoperative adverse
events was higher in the combination of magnesium and beta-blocker group than beta-blocker alone (OR 2.80,
95% CI 1.66-4.71, P = 0.0001).
Conclusions: This meta-analysis offers the more definitive evidence against the prophylactic administration of
intravenous magnesium for prevention of AA after CABG when beta-blockers are routinely administered, and shows
an association with more adverse events in those people who received magnesium.
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Atrial tachyarrhythmias are a common complication of
cardiac surgery, with an incidence of 11% to 40% in
patients after coronary artery bypass grafting (CABG)
and more than 50% in patients after valvular surgery.
Atrial fibrillation (AF), flutter, and multifocal atrial
tachycardia are different forms of atrial tachyarrhythmias,
which have the similar clinical implications in early
recovery of patients after cardiac surgery [1]. Potential
complications of postoperative atrial tachyarrhythmias* Correspondence: wcx0622@gmail.com
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reproduction in any medium, provided the or(POAT) include thromboembolic events, hemodynamic
compromise, delay of clinical recovery after cardiac
surgery, and increased length of stay (LOS) and cost of
hospitalization [2]. AF, occurring after CABG, is also a
major determinant of postoperative stroke [3]. In
addition to potentially increased risk of stroke and
death, patients with recurrent or persistent atrial
arrhythmia (AA) require additional medications, includ-
ing systemic anticoagulation. Physicians and surgeons
have been actively searching for effective strategies to
reduce the incidence of postoperative AA. Several
pharmacologic agents have been used to prevent post-
operative supraventricular arrhythmias with varying. This is an Open Access article distributed under the terms of the Creative
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amiodarone have convincingly been shown to decrease
its incidence [4,5]. Although moderate-dosage cortico-
steroid should be considered for the prevention of AF
in high-risk patients undergoing cardiac surgery, the
interaction between corticosteroids, beta-blockers, and
amiodarone requires further study [6]. The preoperative
administration of digoxin, calcium channel antagonists,
and procainamide has been disappointing [4,7].
Hypomagnesemia has been observed after cardiac
surgery [8,9], and most studies have shown that the
administration of magnesium decreases the incidence
of AA after cardiovascular surgery [10-13]. But the ef-
fectiveness of magnesium has been more controversial,
because that evidence comes from multiple small,
underpowered trials, with conflicting results, probably
because of differences in study design, including the
using of beta-blockers, although a recent meta-analysis
concluded that magnesium is an effective prophylactic
agent for prevention of postoperative AF [14].
To evaluate the effect of magnesium as a sole or
adjuvant agent with currently used prophylactic drugs
such as beta-blocker in suppressing postoperative AA,
several randomized controlled trials (RCTs) have been
examined. However, the results were controversial,
which could possibly be attributable to lack of statistical
power in individual studies. Therefore, we conducted a
meta-analysis of RCTs to evaluate the effect of magnesium
on the prevention of postoperative AA, the hospital LOS,
mortality and adverse effects in addition to beta-blocker
after CABG.
Methods
Publication search and inclusion criteria
This meta-analysis of RCTs was performed in accord-
ance with the Quality of Reporting of Meta-analyses
(QUOROM) consensus guidelines and according to a
protocol that prespecified outcomes, search strategies,
inclusion criteria, and statistical analyses [15]. We
identified studies by a literature search of the PubMed,
Medline, ISI Web of Knowledge, Cochrane library data-
bases and online clinical trial database up to May 2012
with the following key words: “atrial arrhythmias”,
“atrial tachyarrhythmias”, “atrial fibrillation” or “atrial
flutter” plus “coronary artery bypass grafting” plus
“magnesium” plus “beta-blocker”, “beta-blockade” or
“β-blocker”. In addition, we reviewed the reference lists
from all relevant articles to identify additional studies if
necessary. All searches were conducted independently
by 2 authors. The results were compared, and any ques-
tions or discrepancies were resolved through iteration
and consensus.
Criteria for study inclusion: (i) the design was a
prospective, RCT; (ii) both on-pump and off-pumpCABG techniques were included and no limitations
were applied to the number of the grafts used; (iii) all
patients were in sinus rhythm at the time of surgery; (iv)
the intervention was magnesium, as a bolus or continuous
infusion, with a total dose beyond 35 mmol, given as a
prophylactic measure (before the onset of AA) in the inter-
vention group. The intervention group used magnesium in
addition to beta-blocker, and the comparison group just
used the same type of beta-blocker; and (v) the primary
outcome was the incidence of AA after CABG (measured
using a continuous electrocardiogram (ECG) monitoring).
Studies that met any one of the following criteria were
excluded: (i) unspecified methods of detection of AA or un-
specified process of follow-up; (ii) other than magnesium
and beta-blocker, the patients using any other anti-
arrhythmic drugs (e.g. amiodarone) as prophylactic mea-
sures; and (iii) patients with a history of AA or ventricular
arrhythmias or any rhythm other than sinus rhythm on the
electrocardiogram obtained the evening before surgery.
Data extraction and quality assessment
Trials selected for review were screened for information
about patient characteristics, details of administration,
process of treatment, efficacy in preventing postopera-
tive AA, LOS, mortality and adverse effects. All data
were extracted by one author and checked for accuracy
by another author independently. Disagreements were
resolved by consensus, and if necessary, a third author
was required to assess it. We used the Jadad score [16]
to assess the methodological quality of the included
studies. The range of possible scores was 0 to 5.
Statistical methods
One author entered related data into the meta-analysis
software package (RevMan 5.1, the Cochran Collaboration,
Information Management System, http://ims.cochrane.org/
RevMan). The second author crosschecked the printout
against his own data abstraction forms. All statistical
analyses were performed using the RevMan5.1 package.
Clinical homogeneity of included studies was considered
first, by assessing study population, intervention group,
comparison group and outcome. For dichotomous out-
comes, results are expressed as risk ratio with 95% confi-
dence interval (CI). For continuous outcomes, pooled data
are described with the weighted mean difference (WMD)
and 95% CI. Where significant heterogeneity was present,
the studies were examined in detail for the reasons of het-
erogeneity. We assessed heterogeneity with I2, which
describes the percentage of total variation across studies
due to heterogeneity rather than chance. I2 can be calcu-
lated as: I2 = 100% × (Q-df)/Q(Q = Cochrane’s heterogen-
eity statistics, df = degrees of freedom). Negative values of
I2 equaled zero, so that I2 ranged between 0% (ie, no
observed heterogeneity) and 100%. High values would show
Figure 1 Summary of study selection and exclusion process.
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heterogeneous if the chi-square generated by RevMan het-
erogeneity test was associated with a P value <0.05. Where
significant heterogeneity was present, attempts were made
to explain the differences based on the patient clinical char-
acteristics and interventions of the included studies. Ran-
dom effects method was used to address heterogeneity
where appropriate [18]. Where heterogeneity prohibited
pooling, data were presented as a qualitative overview. For
the outcome of interest (occurrence of AA after CABG),
odds ratio (OR) with 95% CI was used. Fixed effects model
was used for pooling where the trials were homogenous.
Where heterogeneity was evident, random effects model
was used for pooling [18].
Results
Characteristics of the included studies
Our initial data search yielded a total of 30 studies
(Figure 1). We excluded 24 studies as they did not meetTable 1 Quality features of 5 studies of RCTs assessed in the




Bert et al. [19] 2001 NS Y Table of
Cook et al. [22] 2009 DB Y NA
Forlani et al. [20] 2002 NS Y compute
random c
Geertman et al. [21] 2004 DB Y NA
Solomon et al. [23] 2000 NS Y NA
DB: double-blind; NS: blinding characteristics of study not specified; NA: unable to aour inclusion criteria. Six potentially relevant studies
were identified [19-24]. One study was excluded
because of duplicate publication [24]. Thus, a total of 5
studies were included in this meta-analysis [19-23]. The
publication dates spanned from 2000 to 2009. Patient
enrolled in a single study ranged from 103 to 694
patients. The total number of randomized patients was
1251. The quality assessment and Jadad score evalu-
ation of the included studies are listed in Table 1. The
patient and study characteristics are shown in Tables 2
and 3, respectively. Most studies reported that magne-
sium in addition to beta-blocker had non-significant
prevention of postoperative AA after CABG [19,21-23].
But one study showed that this strategy could signifi-
cantly decrease the incidence of AF after CABG [20].
Three studies were conducted in USA [19,22,23], one in
Italy [20], and the remaining one in Netherlands [21].
Regimens of magnesium and beta-blocker administra-
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Bert et al. [19] 69/71 62.3/63.8 82.6/76.1 48/49 NA NA 75.4/76.1 21.2/21.2 17.2/18.5
Cook et al.
[22]
347/347 64/64 85.6/83.6 NA 66.9/68 35.7/30.8 88.2/89 1.7/0.9 27.7/24.5
Forlani et al.
[20]
52/51 62/64 91/82 55.3/54.7 63/72 25/38 36/45 7/3 14/16
Geertman
et al. [21]
74/73 63.8/61.7 78.4/79.5 NA 32/30 13.5/8.2 90.5/86.3 NA NA
Solomon
et al. [23]
85/82 62/61 80/73 53/54 NA NA 72/78 3.5/7.3 39/37
Mag: magnesium; BB: beta-blocker; CCB: calcium channel blocker; NA: data not available; LVEF: left ventricular ejection fraction; Preop: preoperative.
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ous ECG through postoperative day 2 to 5, and there-
after a daily ECG study were performed until hospital
discharge for most trials.
The pooled treatment effect
The OR used for estimating the combination of magne-
sium and beta-blocker versus beta-blocker alone to pre-
vent postoperative AA is shown in Figure 2. The pooled
OR and risk ratio (RR) of all studies, by the fixed effects
model, did not show that combination of magnesium
and beta-blocker significantly decreased the incidence
of postoperative AA after CABG verse beta-blocker
alone (OR 1.12, 95% CI 0.86-1.47, P = 0.4; RR 1.09, 95%
CI 0.89-1.34, P = 0.4) and little heterogeneity was indicated
(P = 0.41, I2 =0% and P = 0.44, I2 =0%, respectively). Three
trials reported the effect on hospital LOS with a total of
410 patients (Figure 3) [19,20,23]. LOS after CABG was
similar between the two groups (WMD −0.14 days of stay,
95% CI −0.58 to 0.29, P = 0.51), although minor hetero-
geneity was indicated (P = 0.24, I2 =31%). Three trials
reported data on postoperative mortality [19,21,23], with a







































Postop Iv 24 73
Mag: magnesium; BBs: beta-blockers; Iv: intravenous; Preop: preoperatively; Postop:
tachyarrhythmias; AF: atrial fibrillation; AFL: atrial flutter; SVT: supraventricular tachysignificantly affected by magnesium in addition to beta-
blocker (OR 0.59, 95% CI 0.08-4.56, P = 0.62). The risk
of postoperative adverse events was higher in the com-
bination of magnesium and beta-blocker group than
beta-blocker alone group (OR 2.80, 95% CI 1.66-4.71,
P = 0.0001; Figure 4) and little heterogeneity was indi-
cated (P = 0.70, I2 =0%).
Sensitivity/subgroup analysis
We used subgroup analysis to explore the effect of POAT,
including AF in Figure 5 [19-21,23]. The OR of these stud-
ies, by the fixed effects model, also did not show that com-
bination of magnesium and beta-blocker significantly
decreased the incidence of POAT after CABG versus beta-
blocker alone (OR 1.08, 95% CI 0.71-1.65, P = 0.72). There
was no statistically significant heterogeneity across the
studies (P = 0.26, I2 =25%).
To assess possible differences related to the dose of
magnesium administered, these trials were subdivided
into low (<50 mmol) and high (> =50 mmol) dosages of
magnesium. In the 2 trials with low dose magnesium
(243 patients) [19,20], the percentage of patients with





Definitions of AA with continuous ECG
Propranolol POAT including AF, AFL, or a SVT that was
sustained >5 minutes and warranted
pharmacologic therapy
Atenolol AA lasting >30 minutes or causing
hemodynamic compromise requiring immediate
intervention
Sotalol AF that required treatment for symptoms or
hemodynamic deterioration
Sotalol POAT including AF,AFL, and multifocal atrial
tachycardia
Propranolol AF lasting longer than 1 hour or requiring
therapy as a result of hemodynamic compromise
postoperatively; AA: atrial arrhythmias; POAT: postoperative atrial
cardia.
Figure 2 Forest plot showing the incidence of postoperative AA after CABG. Values are given as the odds ratio [95% confidence interval
(CI)] as determined by the fixed effects model. Mag: magnesium; BB: beta-blocker.
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beta-blocker alone group, but the result was not signifi-
cantly increased (OR 0.71, 95% CI 0.34-1.51, P = 0.38)
(Table 4). In another 3 trials with large dose magnesium
(1008 patients) [21-23], the percentage of patients with
AA was not significantly decreased by using magnesium
in addition to beta-blocker (OR 1.2, 95% CI 0.9-1.6,
P = 0.21) (Table 4).
Of note, sotalol, a new type of beta-blocker [25], is not
only a beta-blocker but also a potent potassium channel
blocker. So we conducted a subgroup analysis and subdi-
vided trials into sotalol group and other beta-blockers
group. In the 2 trials with sotalol (250 patients) [20,21],
the percentage of patients with AA was decreased from
20.6% in the combination of magnesium and sotalol
group to 20.2% in the sotalol alone group (OR 1.03, 95%
CI 0.55-1.96, P = 0.92) (Table 4). In another 3 trials with
other beta-blockers (1001 patients) [19,22,23], the per-
centage of patients with AA was decreased from 24.2%
in the combination of magnesium and other beta-
blockers group to 21.8% in other beta-blockers alone
group (OR 1.14, 95% CI 0.85-1.53, P = 0.38) (Table 4).
Discussion
AF is a common complication of CABG, especially in
the elderly [26,27]. Although long-term sequelae of
postoperative AF are unusual, it frequently results in an
increased length and cost of hospitalization. Aranki
and colleagues found that the length of hospitalization
directly attributable to AF was 4.9 days [27]. ThisFigure 3 Forest plot showing the effect on hospital LOS (days) after C
interval (CI)] as determined by the fixed effects model. Mag: magnesium; Btranslated into more than $10,000 in hospital charges
per patient [23]. Therefore, any intervention that would
reduce the incidence of postoperative AF or AA would
result in a tremendous economic benefit.
AA is a common complication of CABG and beta-
blockers have been shown to decrease the incidence of
postoperative AA. Although magnesium has proven
effective in reducing ventricular tachyarrhythmias and
early mortality in acute myocardial infarction [28], its
role in suppressing POAT remains controversial. This
meta-analysis showed that magnesium could not signifi-
cantly decrease the incidence of postoperative AA after
CABG in addition to beta-blocker. In order to diminish
the extent of AA, we used a subgroup analysis to explore
the influence of POAT, and showed the same result.
Although the meta-analysis by Miller et al. [14] con-
cluded that magnesium administration is an effective
prophylactic measure for the prevention of postopera-
tive AF, only 4 of the 20 studies included in the analysis
were clearly in favor of magnesium administration
[12,20,29,30], with 7 studies showing no reduction in
AF with magnesium prophylaxis [19,31-36]. There are 4
potential reasons for these different results, including:
(i) the potential for β error secondary to small sample
sizes; (ii) different definitions of AF; (iii) different doses
of magnesium administered; and (iv) different use of
concomitant beta-blocker [20]. In order to avoid the
above shortness to some extent, the 5 RCTs in this
meta-analysis have same characteristics, including: (i)
the total dose of magnesium beyond 35 mmol; (ii) theABG. Values are given as the mean difference [95% confidence
B: beta-blocker.
Figure 4 Forest plot showing the adverse events following CABG. Values are given as the odds ratio [95% confidence interval (CI)] as
determined by the fixed effects model. Mag: magnesium; BB: beta-blocker.
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same type of beta-blocker; and (iii) AA was detected by
continuous ECG monitoring. As a result of the over-
whelming data supporting the benefit of beta-blockers
and some encouraging studies on the use of magnesium,
we sought to determine whether magnesium as a sole or
adjuvant agent in the prevention of AA after CABG. As
a result, the combination of magnesium and beta-
blocker did not significantly reduce the incidence of
postoperative AA compared with beta-blocker alone.
One issue with the use of antiarrhythmic agents to
prevent postoperative AA is that the majority of patients
does not develop postoperative AA after cardiac surgery
but would still be exposed to potential side effects of
prophylactic intervention. From our meta-analysis, the
risk of postoperative adverse events was higher in the
combination of magnesium and beta-blocker group than
beta-blocker alone group. The majority of adverse events
were bradycardia and hypotension. An explanation for this
phenomenon could be that intravenous administration of
magnesium prolongs sinoatrial node conduction time,
atrioventricular nodal refractory period, and PR and atrial-
His intervals, as shown in electrophysiologic studies in
healthy human subjects [37]. It is assumed that these
effects are amplified when magnesium is combined with
beta-blocker. Further specific studies are needed to evalu-
ate this hypothesis.
It has been reported that sotalol is not only a beta-
blocker but also a potent potassium channel blocker.
Therefore, we conducted a subgroup analysis and subdi-
vided trials into sotalol group and other beta-blockersFigure 5 Forest plot showing the incidence of POAT after CABG. Value
determined by the fixed effects model. Mag: magnesium; BB: beta-blocker.group. Both sotalol group and other beta-blockers group
showed the same result that magnesium in addition to
beta-blocker could not significantly decrease the incidence
of postoperative AA. At the same time, trials were subdi-
vided into low and high dosages of magnesium, and
showed the same result. Because there was no use of amio-
darone in all the included trials, so we can exclude the im-
pact of amiodarone on the results of this meta-analysis.
Since postoperative AA has been associated with LOS
extended, greater risk of major morbidity and accom-
panying increases in hospital costs, we conducted sub-
group analyses about LOS and mortality. From this
meta-analysis, magnesium in addition to beta-blocker
did not significantly reduce the LOS in this meta-
analysis. Since only 3 studies provided data on LOS,
additional studies or data are warranted. Three trials
reported data on mortality, and the result showed that
the overall mortality was not affected by magnesium
administration in addition to beta-blocker.
Limitations
This meta-analysis is limited by the lack of studies and
complete availability of relevant data, particularly for
LOS, mortality and adverse effects. Each included trial
had different categories of adverse events. For example,
the trial by Bert et al. [19] demonstrated postoperative
adverse events that included myocardial infarction and
ventricular ectopic activity, whereas the trial by Geertman
et al. [21] only included serious bradyarrhythmias and
nonsustained ventricular tachycardia. The research by
Solomon et al. [23] showed the adverse events includings are given as the odds ratio [95% confidence interval (CI)] as
Table 4 Sensitivity and subgroup analysis
Intervention RCTs
(n)







2 0.71 0.34-1.51 0.09 0.38
High dose of
Mag
3 1.2 0.90-1.60 0.85 0.21
Sotalol 2 1.03 0.55-1.96 0.05 0.92
Other BBs 3 1.14 0.85-1.53 0.97 0.38
Mag: magnesium; BBs: beta-blockers; RCTs: randomized controlled trials; OR:
odds ratio; CI: confidence interval.
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number of included studies, we did not have subdivision
of adverse events, such as bradycardia and hypotension
which often occur in the studies. According to the
Cochrane Handbook [38], tests for funnel plot asymmetry
should be used only when there are at least 10 studies
included in the meta-analysis, because when there are fewer
studies the power of the tests is too low to distinguish
chance from real asymmetry. Therefore, Because of 5 arti-
cles in this meta-analysis, the funnel plot was not done in
this meta-analysis. In addition, the number of patients in
most studies was small.
Conclusions
Based on this meta-analysis of RCTs, we can conclude that
magnesium administration isn’t significantly effective for
reducing postoperative AA, hospital LOS and mortality.
Moreover, we observed an association with more adverse
events in those people who received magnesium and beta-
blocker. The combination of magnesium and beta-blocker
does not appear to offer incremental benefit over beta-
blocker alone in the prevention of AA. Considering the
higher adverse effects, the combination of magnesium and
beta-blocker should be contraindicated in patients under-
going CABG. Beta-blockers or amiodarone should be used
for the prevention of postoperative AA. Therefore, we
believe that this meta-analysis offers the more definitive evi-
dence against the prophylactic administration of intraven-
ous magnesium for prevention of AA after CABG when
beta-blockers are routinely administered. In addition, con-
sidering limitations of this meta-analysis, more RCTs are
needed to analyze and do more subgroups analysis in order
to get much more accurate data. Larger studies to further
confirm these clinical benefits and evaluate their cost-
effectiveness would be worthwhile.
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